Cognitive and behavioral dysfunction in Parkinson's disease: Neurochemical and clinicopathological contributions

Journal of Neural Transmission

Volumn 111, Issue 10-11, 2004, Pages 1287-1301

  Zgaljardic, D J ^a,b   Foldi, N S ^b,c   Borod, J C ^b,d  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c WINTHROP UNIVERSITY HOSPITAL   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Behavior; Cognition; Dementia; Lewy bodies; Neurotransmitters; Parkinson's disease

Indexed keywords

DOPAMINE; NEUROTRANSMITTER;

BEHAVIOR DISORDER; BRAIN CORTEX; BRAIN DYSFUNCTION; CENTRAL NERVOUS SYSTEM DEPRESSION; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; DISEASE ASSOCIATION; DOPAMINERGIC SYSTEM; HISTOPATHOLOGY; HUMAN; LEWY BODY; MOTOR DYSFUNCTION; NEUROCHEMISTRY; NORADRENERGIC SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

BRAIN; BRAIN CHEMISTRY; COGNITION DISORDERS; HUMANS; LEWY BODY DISEASE; MENTAL DISORDERS; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE;

EID: 7944228088     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0178-z     Document Type: Review

References (116)

1. Aarsland D, Karlsen K (1999) Neuropsychiatric aspects of Parkinson's disease. Curr Psychiatry Rep 1: 61-68
2. Aarsland D, Ballard C, Larsen JP, McKeith I (2001) A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 16: 528-536
3. Aarsland D, Hutchinson M, Larsen JP (2003) Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 18: 937-941
4. Agid Y, Javoy-Agid F, Ruberg M (1987) Biochemistry of neurotransmitters in Parkinson's disease. In: Marsden CD, Fahn S (eds) Movement disorders, vol 2. Butterworth, London, pp 166-230
5. Albert ML, Feldman RG, Willis AL (1974) The 'subcortical dementia' of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 37: 121-130
6. Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 9: 357-381
7. Alexander GE, Crutcher MD, DeLong MR (1990) Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 85: 119-146
8. Apaydin H, Ahlskog E, Parisi JE, Boeve BF, Dickson DW (2002) Parkinson's disease neuropathology: later-developing dementia and loss of levodopa response. Arch Neurol 59: 102-112
9. Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T (1998) Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study. J Neurol Neurosurg Psychiatry 65: 155-163
10. Assal F, Cummings JL (2002) Neuropsychiatrie symptoms in the dementias. Curr Opin Neurol 15: 445-450
11. Aubert I, Aranjo DM, Cecyre D, Robitaille Y, Gauthier S, Quirion R (1992) Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem 58: 529-541
12. Ballard C, O'Brien J, Gray A, Cormack F, Ayre G, Rowan E, Thompson P, Bucks R, McKeith I, Walker M, Tovee M (2001) Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease. Arch Neurol 58: 977-982
13. Barbosa ER, Limongi JCP, Cummings JL (1997) Parkinson's disease. Psychiatr Clin North Am 20: 769-790
14. 1 agonist. Clin Neuropharmacol 21: 108-117
15. Bedard MA, Pillon B, Dubois B, Duchesne N, Masson H, Agid Y (1999) Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcorticofrontal syndrome. Brain Cogn 40: 289-313
16. Bertrand E, Lechowicz W, Szpak GM, Dymecki J (1997) Quantitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease. Folia Neuropathol 35: 80-86
17. Boller F, Mizutani T, Roessmann U, Gambetti P (1980) Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations. Ann Neurol 7: 329-335
18. Briley M (1993) Noradrenergic mechanisms in Parkinson's disease. Trends Pharmacol Sci 14: 33-34
19. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS (1979) Cognitive deficits caused by regional depletion of dopamine in prefrontal cortex of rhesus monkeys. Science 205: 929-932
20. Byrne EJ, Lennox G, Lowe J, Godwin-Austen RB (1989) Diffuse Lewy body disease: clinical features in 15 cases. J Neurol Neurosurg Psychiatry 52: 709-711
21. Calderon J, Perry RJ, Erzinclioglu SW, Berrios GE, Dening TR, Hodges JR (2001) Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer's disease. J Neurol Neurosurg Psychiatry 70: 157-164
22. Carbon M, Marie RM (2003) Functional imaging of cognition in Parkinson's disease. Curr Opin Neurol 16: 475-480
23. Carbon M, Ma Y, Barnes A, Dhawan V, Chaly T, Ghilardi MF, Eidelberg D (2004) Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism. NeuroImage 21: 1384-1390
24. Cercy SP, Bylsma FW (1997) Lewy bodies and progressive dementia: a critical review and meat-analysis. J Int Neuropscyhol Soc 3: 179-194
25. Chinaglia G, Alvarez FJ, Probst A, Palacios JM (1992) Mesocortical and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study with [3H] mazindol. Neurosci 49: 317-327
26. Chinaglia G, Landwehrmeyer B, Probst A, Palacios JM (1993) Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H] citalopram. Neurosci 54: 691-699
27. Collerton D, Burn D, McKeith I, O'Brien J (2003) Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord 16: 229-237
28. Colosimo C, Hughes AJ, Kilford L, Lees AJ (2003) Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 74: 852-856
29. Cools R, Barker RA, Sahakian BJ, Robbins TW (2001) Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task commands. Cereb Cortex 12: 1136-1143
30. Cummings JL, Diaz C, Levy M, Binetti G, Litvan I (1996) Neuropsychiatric syndromes in neurodegenerative diseases: frequency and significance. Sem Clin Neuropsychiatry 1: 241-247
31. Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B (2002) Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia 40: 2257-2267
32. Devinsky O, Morrell MJ, Vogt BA (1995) Contributions of anterior cingulate cortex to behavior. Brain 118: 279-306
33. Downes JJ, Priestly NM, Doran M, Ferran J, Ghadiali E, Cooper P (1999) Intellectual, mnemonic and frontal functions in dementia with Lewy bodies: a comparison with early and advanced Parkinson's disease. Behav Neurol 11: 173-183
34. Dubois B, Pillon B (1997) Cognitive deficits in Parkinson's disease. J Neurol 244: 2-8
35. Dubois B, Ruberg M, Javoy-Agid F, Ploska A, Agid Y (1983) A subcortico-cortical cholinergic system is affected in Parkinson's disease. Brain Res 288: 213-218
36. Dubois B, Danze F, Pillon B, Cusimano G, Lhermitte F, Agid Y (1987) Cholinergic-dependent cognitive deficits in Parkinson's disease. Ann Neurol 22: 26-30
37. Dubois B, Boller F, Pillon B, Agid Y (1991) Cognitive deficits in Parkinson's disease. In: Boller F, Grafman J, Corkin S (eds) Handbook of neuropsychology, vol 5. Eisevier, Amsterdam, pp 195-240
38. Emre M (2003a) Dementia associated with Parkinson's disease. Lancet Neurol 2: 229-237
39. Emre M (2003b) What causes mental dysfunction in Parkinson's disease? Mov Disord 18: S63-S71
40. Everitt BJ, Robbins TW (1997) Central cholinergic systems and cognition. Annu Rev Psychol 48: 649-684
41. Everitt BJ, Robbins TW, Selden NRW (1990) Functions of the locus coeruleus noradrenergic system: a neurobiological and behavioral synthesis. In: Heal DJ, Marsden CD (eds) The pharmacology of noradrenaline in the central nervous system. Oxford University Press, New York, pp 349-378
42. Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G (2002) Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 23: 41-43
43. Foldi NS, Schaefer LA, White REC, Johnson R Jr, Berger JT, Carney M, Macina LO (2004) Effects of graded levels of physical similarity and density on visual selective attention in patients with Alzheimer's disease. Neuropsychology (in press)
44. Forno LS (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55: 259-272
45. Gibb WR, Luthert PJ, Janota I, Lantos PL (1989) Cortical Lewy body dementia: clinical features and classification. J Neurol Neurosurg Psychiatry 52: 185-192
46. Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD (2003) Rivastigmine (Excelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand 108: 368-373
47. Gnanalingham KK, Byrne EJ, Thornton A, Sambrook MA, Bannister P (1997) Motor and cognitive function in Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry 62: 243-252
48. Gotham AM, Brown RG, Marsden CD (1988) 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain 111: 299-321
49. Green J, McDonald WM, Vitek MD, Evatt M, Freeman A, Haber M, Bakay RA, Triche S, Sirockman B, DeLong MR (2002) Cognitive impairments in advanced PD without dementia. Neurology 59: 1320-1324
50. Greenberg SM, Tennis M, Brown LB, Gomez-Isla T, Hayden DL, Schoenfeld DA, Walsh KL, Corwin C, Daffner KR, Friedman P, Meadows M, Sperling RA, Growdon JH (2000) Donepezil therapy in clinical practice. Arch Neurol 57: 94-99
51. Growdon JH, Kieburtz K, McDermott MP, Panisset M, Friedman JH, the Parkinson Study Group (1998) Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Neurology 50: 1327-1331
52. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thai L, Pay MM, Hofstetter R, Klauber M (1990) The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 40: 1-8
53. Hantz P, Caradoc G, Caradoc T, Weatherall M, Dixon G (1994) Depression in Parkinson's disease. Am J Psychiatry 151: 1010-1014
54. Hornykiewicz O, Pifl C (1994) The validity of the MPTP primate model for neurochemical pathology of idiopathic Parkinson's disease. In: Briley M, Marien M (eds) Noradrenergic mechanisms in Parkinson's disease. CRC Press, Boca Raton, pp 59-71
55. Hutchinson M, Fazzini E (1996) Cholinesterase inhibition in Parkinson's disease [letter]. J Neurol Neurosurg Psychiatry 61: 324-325
56. Jankovic J (2000) Complications and limitations of drug therapy for Parkinson's disease. Neurology 55: S2-S6
57. Kaasinen V, Aalto S, Nagren K, Hietala J, Sonninen P, Rinne JO (2003) Extrastriatal dopamine D(2) receptors in Parkinson's disease: a longitudinal study. J Neural Transm 110: 591-601
58. Kish SJ, Rajput A, Gilbert J, Rozdilsky B, Chang LJ, Shannak K, Hornykiewicz O (1986) Elevated aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss. Ann Neurol 20: 26-31
59. Kremer J, Starkstein SE (2000) Affective disorders in Parkinson's disease. Int Rev Psychiatry 12: 290-297
60. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, Wieland DM, Koeppe RA (1996) In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 40: 399-410
61. Kulisevsky J, Garcia-Sanchez C, Berthier ML, Barbanoj M, Pascual-Sedano B, Gironell A, Estevez-Gonzalez A (2000) Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 15: 613-626
62. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM (1992) L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal dysfunction. Psychopharmacol 107: 394-404
63. Levin BE, Llabre MM, Weiner WJ (1988) Parkinson's disease and depression: psychometric properties of the Beck Depression Inventory. J Neurol Neurosurg Psychiatry 51: 1401-1404
64. Lewis SJ, Cools R, Robbins TW, Dove A, Barker RA, Owen AM (2003) Using executive heterogeneity to explore the nature of working memory deficits in Parkinson's disease. Neuropsychologia 41: 645-654
65. Lichter DG (2000) Movement disorders and frontal-subcortical circuits. In: Lichter DG, Cummings JL (eds) Frontal-subcortical circuits in psychiatric and neurological disorders. The Guildford Press, New York, pp 260-313
66. Litvan I, MacIntyre A, Goetz CG, Wennig GK, Jellinger KA, Verny M, Bartko JJ, Jancovic J, McKee A, Brandel JP, Chaudkuri R, Lai EC, D'Olhaberriague L, Pearce RKB, Agid Y (1998) Accuracy of the clinical diagnoses of Lewy Body disease, Parkinson's disease, and dementia with Lewy bodies. Arch Neurol 55: 969-978
67. Litvan I, Phipps M, Pharr VL, Hallet M, Grafman J, Salazar A (2001) Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 57: 467-473
68. Mahieux F, Fenelon G, Flahault A, Manifacier MJ, Michelet D, Boller F (1998) Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 64: 178-183
69. Mayeux R, Stern Y, Sano M, Williams JB, Cote LJ (1988) The relationship of serotonin to depression in Parkinson's disease. Mov Disord 3: 237-244
70. Mayberg HS (2000) Depression and frontal-subcortical circuits: focus on prefrontal limbic interactions. In: Lichter DG, Cummings JL (eds) Frontal-subcortical circuits in psychiatric and neurological disorders. The Guildford Press, New York, pp 177-206
71. Mayberg HS, Solomon DH (1995) Depression in Parkinson's disease: a biochemical and organic viewpoint. Adv Neurol 65: 49-60
72. McKeith I, Burn D (2000) Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurol Clin 18: 865-883
73. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen ENH, Ballard C, de Vos RAI, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium of DLB international workshop. Neurology 47: 1113-1124
74. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 356: 2031-2036
75. Mentis MJ, Delalot D, Dhawan V, Eidelberg D (2003a) Anticholinesterase effect on brain function and learning in Parkinson's disease. Biol Psychiatry 53: 160S
76. Mentis MJ, Dhawan V, Nakamura T, Ghilardi MF, Feigin A, Edwards C, Ghez C, Eidelberg D (2003b) Enhancement of brain activation during trial-and-error sequence learning in early PD. Neurology 60: 612-619
77. Menza MA, Mark MH (1994) Parkinson's disease and depression: the relationship to disability and personality. J Neuropsychiatry Clin Neurosci 6: 165-169
78. Mori S (2002) Responses to Donepezil in Alzheimer's disease and Parkinson's disease. Ann NY Acad Sci 977: 493-500
79. Morrison CE, Borod JC, Brin MF, Raskin SA, Germano IM, Weisz DJ, Olanow CW (2000) A program for neuropsychological investigation of deep brain stimulation (PNIDBS) in movement disorder patients: development, feasibility, and preliminary data. Neuropsychiatr Neuropsychol Behav Neurol 13: 204-219
80. Mosimann UP, McKeith IG (2003) Dementia with Lewy bodies - diagnosis and treatment. Swiss Med Wkly 133: 131-142
81. Nakano I, Hirano A (1984) Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 15: 415-418
82. Nordberg A (2002) Understanding changes in cholinergic function: implications for treating dementia. J Clin Psychiatry 63: 259-269
83. Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Sonninen P, Rinne J (2001) Rate of progression in Parkinson's disease: a 6-[18F] fluoro-L-dopa PET study. Mov Disord 16: 608-615
84. Ondo WG, Jankovic J (1998) Parkinson's disease. In: Krauss JK, Grossman RG, Jankovic J (eds) Pallidal surgery for the treatment of Parkinson's disease and movement disorders. Lippincott-Raven, New York, pp 67-83
85. Pahwa R, Paolo A, Tröster A, Koller W (1998) Cognitive impairment in Parkinson's disease. Eur J Neurol 5: 431-441
86. Palazzini E, Soliveri P, Filippini G, Fetoni V, Zappacosta B, Scigliano G, Monza D, Caraceni T, Girotti F (1995) Progression of motor and cognitive impairment in Parkinson's disease. J Neurol 242: 535-540
87. Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 50: 743-755
88. Perl DP, Olanow W, Calne D (1998) Alzheimer's disease and Parkinson's disease: distinct entities or extremes of a spectrum of neurodegeneration? Ann Neurol 44: S19-S31
89. Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, Blessed G, Fairbairn A, Tomlinson BE, Perry RH (1985) Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 48: 413-421
90. Pillon B, Dubois B, Cusimano G, Bonnet A, Lhermitte F, Agid Y (1989) Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions? J Neurol Neurosurg Psychiatry 52: 201-206
91. Pluck GC, Brown RG (2002) Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatry 73: 636-642
92. Raskin SA, Borod JC, Tweedy J (1990) Neuropsychological aspects of Parkinson's disease. Neuropsychol Rev 1: 185-221
93. Rinne JO, Rummukainen J, Paljarui L, Rinne UK (1989) Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 26: 47-50
94. Rinne JO, Myllykyla T, Lonnberg P, Marjamaki P (1991) A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res 547: 167-170
95. Rogers JD, Brogan D, Mirra SS (1985) The nucleus basalis of Meynert in neurological disease: a quantitative morphological study. Ann Neurol 17: 163-170
96. Rosvold HE (1972) The frontal lobe system: cortical-subcortical interrelationships. Acta Neurobiol Exp 32: 439-460
97. Saint-Cyr JA, Taylor AE, Lang AE (1993) Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology 43: S47-S52
98. Scatton B, Javoy-Agid F, Roquier L, Dubois B, Agid Y (1983) Reduction of cortical dopamine, noradrenaline, serotonin, and their metabolites in Parkinson's disease. Brain Res 275: 321-328
99. Schneider JS, Kovelowski CJ (1990) Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res 519: 122-128
100. Sharpe MH (1992) Auditory attention in early Parkinson's disease: an impairment in focused attention. Neuropsychologia 30: 101-106
101. Shinotoh H, Namba H, Yamaguchi M, Fukushi K, Nagatsuka S, Iyo M, Asahina M, Hattori T, Tanada S, Irie T (1999) Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Ann Neurol 46: 62-69
102. Soldani P, Fornai F (1999) The functional anatomy of noradrenergic neurons in Parkinson's disease. Funct Neurol 14: 97-109
103. Stern Y, Langston JW (1985) Intellectual changes in patients with MPTP-induced parkinsonism. Neurology 35: 1506-1509
104. Stuss DT, van Reekum R, Murphy KJ (2000) Differentiation of states and causes of apathy. In: Borod JC (ed) The neuropsychology of emotion. Oxford University Press, London, pp 340-363
105. Swainson R, Rogers RD, Sahakian BJ, Summers BA, Polkey CE, Robbins TW (2000) Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 38: 596-612
106. Tekin S, Cummings JL (2002) Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res 53: 647-654
107. Torak RM, Morris JC (1988) The association of the ventral tegmental area histopathology with adult dementia. Arch Neurol 45: 211-218
108. Tröster AI, Woods SP (2003) Neuropsychological aspects of Parkinson's disease and parkinsonian syndromes. In: Pahwa R, Lyons KE, Koller WC (eds) Handbook of Parkinson's disease. Marcel Dekker, New York, pp 127-157
109. Werber EA, Rabey JM (2001) The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm 108: 1319-1325
110. Wolters EC (2001) Intrinsic and extrinsic psychosis in Parkinson's disease. J Neurol 248: 22-27
111. Yeterian EH, Pandya DN (1991) Prefrontostriatal connections in relation to cortical architectonic organization in rhesus monkeys. J Comp Neurol 312: 43-67
112. Zakzanis KK, Freedman M (1999) A neuropsychological comparison of demented and non-demented patients with Parkinson's disease. Appl Neuropsychol 6: 129-146
113. Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson disease. Arch Neurol 60: 337-341
114. Zgaljardic DJ, Borod JC, Foldi NS, Mattis P (2003) A review of the cognitive and behavioral sequelae of Parkinson's disease: relationship to frontostriatal circuitry. Cogn Behav Neurol 16: 193-210
115. Zgaljardic DJ, Borod JC, Foldi NS, Mattis P, Gordon MF, Feigin A, Eidelberg D (2004) A neuropsychological evaluation of cognitive and behavioral impairments in Parkinson's disease: relationships to frontostriatal circuitry (in press)
116. Zweig RM, Cardillo JE, Cohen M, Giere S, Hedreen JC (1993) The locus ceruleus and dementia in Parkinson's disease. Neurology 43: 986-991